Resolution of Macular Edema secondary to rituximab after intravitreal dexamethasone: A case report and a review of the literature
- PMID: 37644808
- DOI: 10.1177/11206721231199120
Resolution of Macular Edema secondary to rituximab after intravitreal dexamethasone: A case report and a review of the literature
Abstract
Purpose: to report a case of bilateral macular edema (ME) secondary to Rituximab infusions in a woman affected by IgG4-Related Disease and to review of prior cases of ME related to Rituximab.
Observations: ME completely resolved after Intravitreal Dexamethasone Implant (IDI).
Conclusions and importance: ME is a rare complication after Rituximab infusions and very few cases are reported in the literature. Usually, ME occurs a few weeks after systemic administration and is probably related to a local release of cytokines. It resolves with oral, subtenon or intravitreal steroids. Our case is the first showing that IDI is a safe and effective treatment in ME secondary to Rituximab. Rituximab is not required to be discontinued if treatment for ME is started.
Keywords: IgG4 related disease (IgG4-RD); Macular Edema; rituximab.
Conflict of interest statement
Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Similar articles
-
The short-term efficacy of intravitreal ranibizumab, aflibercept and dexamethasone implant in the treatment of macular edema due to non-ischemic central retinal vein occlusion.Int Ophthalmol. 2019 Apr;39(4):891-901. doi: 10.1007/s10792-018-0890-6. Epub 2018 Mar 17. Int Ophthalmol. 2019. PMID: 29550932
-
Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial.Ophthalmology. 2019 Feb;126(2):283-295. doi: 10.1016/j.ophtha.2018.08.021. Epub 2018 Sep 27. Ophthalmology. 2019. PMID: 30269924 Free PMC article. Clinical Trial.
-
Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience.Graefes Arch Clin Exp Ophthalmol. 2018 Aug;256(8):1441-1448. doi: 10.1007/s00417-018-4016-7. Epub 2018 May 31. Graefes Arch Clin Exp Ophthalmol. 2018. PMID: 29855706
-
Dexamethasone intravitreal implant (OZURDEX®) for macular edema secondary to noninfectious uveitis: a review of the literature.Ther Deliv. 2019 Jun 1;10(6):343-351. doi: 10.4155/tde-2019-0024. Epub 2019 Jun 11. Ther Deliv. 2019. PMID: 31184554 Review.
-
Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials.Indian J Ophthalmol. 2019 Nov;67(11):1800-1809. doi: 10.4103/ijo.IJO_382_19. Indian J Ophthalmol. 2019. PMID: 31638037 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
